Effect of denosumab vs zoledronic acid on bone turnover markers in postmenopausal women with severe osteoporosis

Trial Profile

Effect of denosumab vs zoledronic acid on bone turnover markers in postmenopausal women with severe osteoporosis

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Oct 2013

At a glance

  • Drugs Denosumab (Primary) ; Zoledronic acid
  • Indications Postmenopausal osteoporosis
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 06 Oct 2013 Results presented at the 35th Annual Meeting of the American Society for Bone and Mineral Research.
    • 02 Nov 2012 New trial record
    • 16 Oct 2012 Results presented at the 34th Annual Meeting of the American Society for Bone and Mineral Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top